HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggable Proteome (R03 Clinical Trial Not Allowed)
This NIH R03 pilot opportunity is generally aimed at research institutions; eligible applicants include higher-education institutions, faith-based/community organizations, tribal governments, and o…
- Deadline
- Jul 16, 2026
- Posted
- Dec 11, 2024
- Award amount
- Up to $100,000
In plain English
This NIH R03 pilot opportunity is generally aimed at research institutions; eligible applicants include higher-education institutions, faith-based/community organizations, tribal governments, and other entities, but foreign (non-U.S.) organizations are not eligible to apply (foreign components of U.S. organizations may be allowed). It funds early-stage research to identify new druggable protein targets for pain as part of the NIH HEAL initiative, with awards up to about $100,000 and no clinical trials allowed. Applicants typically need research infrastructure and a named investigator. The deadline is within about three weeks.
AI-generated summary to help you decide quickly — verify the official eligibility rules before applying.
Who can apply
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
About this grant
The purpose of this notice of funding opportunity (NOFO) is to solicit applications for pilot projects to identify new druggable targets for pain within the understudied druggable proteome. Awards will support generation of preliminary data and/or tools around eligible understudied protein(s) listed in this NOFO. This NOFO is intended to jumpstart research on understudied proteins within the context of pain and pain management and provide applicants with sufficient funding to perform basic biochemical and/or biological work to further the characterization of understudied proteins to identify new druggable targets for pain. This NOFO is part of the NIH Helping to End Addiction Long Term (HEAL) initiative to accelerate the development of novel medications to treat all aspects of the opioid addiction cycle, including progression to chronic use, withdrawal symptoms, craving, relapse, and overdose.
Let AI draft your application
Your first draft is free: a narrative and budget outline tailored to this grant, emailed to you. Drafts are written in a nightly batch, so it arrives by email later — not instantly on this page.
Application Kit — $49 one-time
Winner intelligence + a first-draft narrative grounded in applications that actually won. One payment, no subscription.
Get the Application Kit →Related grants
Other open grants funding Education, Health and Income Security and Social Services — soonest deadline first.
BRAIN Initiative: Next-Generation Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3 Clinical Trial Optional)
National Institutes of Health · Amount varies · Due Sep 28, 2026
BRAIN Initiative: Clinical Studies to Advance Next-Generation Devices for Recording and Modulation in the Human Central Nervous System (UH3 Clinical Trial Optional)
National Institutes of Health · Amount varies · Due Sep 28, 2026
Substance Use/Substance Use Disorder Dissertation Research Award (R36 Clinical Trials Not Allowed)
National Institutes of Health · Amount varies · Due in 16 days
Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2024, 2025, and 2026 (P50 Clinical Trial Required)
National Institutes of Health · Amount varies · Due Sep 25, 2026
National Cancer Institute Youth Enjoy Science Research Education Program (R25 Clinical Trial Not Allowed)
National Institutes of Health · Up to $400K · Due Sep 28, 2026
Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed)
National Institutes of Health · Amount varies · Due in 16 days
Also listed under National Institutes of Health, Education Grants and Health Grants.
Source: public records via Grants.gov. UseGrants is an independent aggregator, not affiliated with any funding agency. Always confirm details on the official listing before applying.